A look between the cardiomyocytes: The extracellular matrix in heart failure

Mayo Clinic Proceedings

Volumn 81, Issue 1, 2006, Pages 71-76

  Miner, Edward C ^a,b   Miller, Wayne L ^a  

^a Mayo Clinic   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBROTIC AGENT;

CELL INTERACTION; CONNECTIVE TISSUE; DISEASE COURSE; DRUG TARGETING; EXTRACELLULAR MATRIX; HEART FAILURE; HEART LEFT VENTRICLE; HEART MUSCLE; HEART MUSCLE CELL; HEART MUSCLE INJURY; HEART MUSCLE METABOLISM; HEART MUSCLE PERFUSION; PATHOGENESIS; REVIEW;

EID: 30144445032     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/81.1.71     Document Type: Review

References (68)

1. Weber KT. From inflammation to fibrosis: a stiff stretch of highway [editorial]. Hypertension. 2004;43:716-719.
2. Weber KT. Cardiac interstitium in health and disease: the fibrillar collagen network. J Am Coll Cardiol. 1989;13:1637-1652.
3. Jugdutt BI. Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough? Circulation. 2003;108:1395-1403.
4. Eghbali M, Czaja MJ, Zeydel M, et al. Collagen chain mRNAs in isolated heart cells from young and adult rats. J Mol Cell Cardiol. 1988;20:267-276.
5. Eghbali M, Blumenfeld OO, Seiner S, et al. Localization of types I, III and IV collagen mRNAs in rat heart cells by in situ hybridization. J Mol Cell Cardiol. 1989;21:103-113.
6. Robinson TF, Factor SM, Sonnenblick EH. The heart as a suction pump. Sci Am. 1986;254:84-91.
7. Weber KT. Fibrosis and hypertensive heart disease. Curr Opin Cardiol. 2000;15:264-272.
8. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L, CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation. 1990;82:1730-1736.
9. Struthers AD. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail. 1996;2:47-54.
10. Pitt B, Zannad F, Remme WJ, et al. Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-717.
11. Zannad F, Alla F, Dousset B, Perez A, Pitt B, RALES Investigators. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES) [published correction appears in Circulation. 2001;103:476]. Circulation. 2000;102:2700-2706.
12. Ramires FJ, Mansur A, Coelho O, et al. Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol. 2000;85:1207-1211.
13. Stier CT Jr, Koenig S, Lee DY, Chawla M, Frishman WH. Aldosterone and aldosterone antagonism in cardiovascular disease: focus on eplerenone (Inspra). Heart Dis. 2003;5:102-118.
14. Pitt B, Remme W, Zannad F, et al, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction [published correction appears in N Engl J Med. 2003;348:2271]. N Engl J Med. 2003;348:1309-1321.
15. Brilla CG. Aldosterone and myocardial fibrosis in heart failure. Herz. 2000;25:299-306.
16. Zhou G, Kandala JC, Tyagi SC, Katwa LC, Weber KT. Effects of angiotensin II and aldosterone on collagen gene expression and protein turn-over in cardiac fibroblasts. Moll Cell Biochem. 1996;154:171-178.
17. Rombouts K, Wielant A, Hellemans K, Schuppan D, Geerts A. Influence of aldosterone on collagen synthesis and proliferation of rat cardiac fibroblasts. Br J Pharmacol. 2001;134:224-232.
18. Young M, Fullerton M, Dilley R, Funder J. Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest. 1994;93:2578-2583.
19. Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol. 1993;25:563-575.
20. 2 in peripheral blood mononuclear cells. Circulation. 2005;111:51-57.
21. Khalil ME, Basher AW, Brown EJ Jr, Alhaddad IA. A remarkable medical story: benefits of angiotension-converting enzyme inhibitors in cardiac patients. J Am Coll Cardiol. 2001;37:1757-1764.
22. Schnee JM, Hsueh WA. Angiotensin II, adhesion, and cardiac fibrosis. Cardiovasc Res. 2000;46:264-268.
23. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev. 2000;52:11-34.
24. Lijnen PJ, Petrov W, Fagard RH. Angiotensin II-induced stimulation of collagen secretion and production in cardiac fibroblasts is mediated via angiotensin II subtype 1 receptors. J Renin Angiotensin Aldosterone Syst. 2001;2:117-122.
25. Kim S, Ohta K, Hamaguchi A, Yukimura T, Miura K, Iwao H. Angiotensin II induces cardiac phenotypic modulation and remodeling in vivo in rats. Hypertension. 1995;25:1252-1259.
26. Mervaala E, Muller DN, Schmidt F, et al. Blood pressure-independent effects in rats with human renin and angiotensinogen genes. Hypertension. 2000;35:587-594.
27. Alexander BT, Cockrell KL, Rinewalt AN, Herrington JN, Granger JP. Enhanced renal expression of preproendothelin mRNA during chronic angiotensin II hypertension. Am J Physiol Regul Integr Comp Physiol. 2001;280: R1388-R1392.
28. Bohlender J, Gerbaulet S, Kramer J, Gross M, Kirchengast M, Dietz R. Synergistic effects of AT(1) and ET(A) receptor blockade in a transgenic, angiotensin II-dependent, rat model. Hypertension. 2000;35:992-997.
29. Urata H, Hoffmann S, Ganten D. Tissue angiotensin II system in the human heart. Eur Heart J. 1994;15(suppl D):68-78.
30. Matsumoto T, Wada A.Tsutamoto T, Ohnishi M, Isono T, Kinoshita M. Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure. Circulation. 2003;I07:2555-2558.
31. Hara M, Ono K, Hwang MW, et al. Evidence for a role of mast cells in the evolution to congestive heart failure. J Exp Med. 2002;195:375-381.
32. Spieker LE, Noll G, Ruschitzka FT, Luscher TF. Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future? J Am Coll Cardiol.2001;37:1493-1505.
33. Stewart DJ, Cernacek P, Costello KB, Rouleau JL. Elevated endothelin-1 in heart failure and loss of normal response to postural change. Circulation. 1992;85:510-517.
34. McMurray JJ, Ray SG, Abdullah I, Dargie HJ, Morton JJ. Plasma endothelin in chronic heart failure. Circulation. 1992;85:1374-1379.
35. Kahaleh MB. Endothelin, an endothelial-dependent vasoconstrictor in scleroderma: enhanced production and profibrotic action. Arthritis Rheum. 1991;34:978-983.
36. Katwa LC, Guarda E, Weber KT. Endothelin receptors in cultured adult rat cardiac fibroblasts. Cardiovasc Res. 1993;27:2125-2129.
37. Guarda E, Katwa LC, Myers PR, Tyagi SC, Weber KT. Effects of endothelins on collagen turnover in cardiac fibroblasts. Cardiovasc Res. 1993; 27:2130-2134.
38. Harada M, Itoh H, Nakagawa O, et al. Significance of ventricular myocytes and nonmyocytes interaction during cardiocyte hypertrophy, evidence for endothelin-1 as a paracrine hypertrophic factor from cardiac non-myocytes. Circulation. 1997;96:3737-3744.
39. Ramires FJ, Nunes VL, Fernandes F, Mady C, Ramires JA. Endothelins and myocardial fibrosis. J Card Fail. 2003;9:232-237.
40. A Receptor Blockade Trial (HEAT). Circulation. 2002;106:2666-2672.
41. Torre-Amione G, Young JB, Colucci WS, et al. Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. J Am Coll Cordial. 2003;42:140-147.
42. Kalra PR, Moon JC, Coats AJ. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol. 2002;85:195-197.
43. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A, V-HeFT VA Cooperative Studies Group. Plasma norepinephrine, plasma renin activity, and congestive heart failure: relations to survival and the effects of - therapy in V-HeFT II. Circulation. 1993;87(6, suppl):V140-V148.
44. Shibata MC, Flather MD, Wang D. Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure. Eur J Heart Fail. 2001;3:351-357.
45. Earth W, Deten A, Bauer M, Reinohs M, Leicht M, Zimmer HG. Differential remodeling of the left and right heart after norepinephrine treatment in rats: studies on cytokines and collagen. J Mol Cell Cardiol. 2000; 32:273-284.
46. Bhambi B, Eghbali M. Effect of norepinephrine on myocardial collagen gene expression and response of cardiac fibroblasts after norepinephrine treatment. Am J Pathol. 1991;139:1131-1142.
47. Akiyama-Uchida Y, Ashizawa N, Ohtsuru A, et al. Norepinephrine enhances fibrosis mediated by TGF-beta in cardiac fibroblasts. Hypertension. 2002;40:148-154.
48. Dom GW II. Adrenergic pathways and left ventricular remodeling. J Card Fail. 2002;8(6, suppl):S370-S373.
49. Pick R, Jalil JE, Janicki JS, Weber KT. The fibrillar nature and structure of isoproterenol-induced myocardial fibrosis in the rat. Am J Pathol. 1989; 134:365-371.
50. Poole-Wilson PA, Swedberg K, Cleland JG, et al, Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362:7-13.
51. Grimm D, Huber M, Jabusch HC, et al. Extracellular matrix proteins in cardiac fibroblasts derived from rat hearts with chronic pressure overload: effects of beta-receptor blockade. J Mol Cell Cardiol. 2001;33:487-501.
52. Suryaprasad AG, Prindiville T. The biology of TNF blockade. Autoimmun Rev. 2003;2:346-357.
53. Baumgarten G, Knuefermann P, Kalra D, et al. Load-dependent and -independent regulation of proinflammatory cytokine and cytokine receptor gene expression in the adult mammalian heart. Circulation. 2002;105:2192-2197.
54. Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, Mann DL. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest. 1993;92:2303-2312.
55. Bradham WS, Bozkurt B, Gunasinghe H, Mann D, Spinale FG. Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: a current perspective. Cardiovasc Res. 2002;53:822-830.
56. Bozkurt B, Torre-Amione G, Warren MS, et al. Results of targeted antitumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation. 2001;103:1044-1047.
57. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT, ATTACH Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure: results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) trial. Circulation. 2003;107:3133-3140.
58. Border WA, Noble NA. Transforming growth factor beta in tissue fibresis. N Eng J Med. 1994;331:1286-1292.
59. Lijnen PJ, Petrov VV, Fagard RH. Induction of cardiac fibrosis by transforming growth factor-beta(1). Mol Genet Metab. 2000;71:418-435.
60. Sun Y, Zhang JQ, Zhang J, Ramires FJ. Angiotensin II, transforming growth factor-betal and repair in the infarcted heart. J Mol Cell Cardiol. 1998; 30:1559-1569.
61. Roberts AB, Sporn MB, Assoian RK, et al. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci U S A. 1986;83:4167-4171.
62. Yoo KH, Thornhill BA, Wolstenholme JT, Chevalier RL. Tissue-specific regulation of growth factors and clusterin by angiotensin II. Am J Hypertens. 1998;11(6, pt 1):715-722.
63. Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991;5:2145-2154.
64. Rohde L, Ducharme A, Arroyo L, et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation. 1999;99:3063-3070.
65. Mukherjee R, Brinsa TA, Dowdy KB, et al. Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation. 2003;107:618-625.
66. Hoekstra R, Eskens FA, Verweij J. Matrix metalloproteinase inhibitors: current developments and future perspectives. Oncologist. 2001;6:415-427.
67. Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol. 2002;3:207-214.
68. Yarbrough WM, Mukherjee R, Escobar GP, et al. Selective targeting and timing of matrix metalloproteinase inhibition in post-myocardial infarction remodeling. Circulation. 2003;108:1753-1759.